(AOF) – Innate Pharma announced today the expiry of the waiting period provided for by the Hart-Scott-Rodino Antitrust Improvements Act and the entry into force of the license agreement with Sanofi, scheduled since December 19, 2022 Sanofi has obtained an exclusive license for the multispecific NK cell engaging antibody program targeting B7H3. This program comes from Innate’s Anket (Antibody-based NK Cell Engager Therapeutics) platform.
Following the selection of each drug candidate, Sanofi will be responsible for the development, manufacturing and commercialization of the products. Under the terms of the agreement, Innate will receive an upfront payment of €25 million and up to €1.35 billion in milestone payments linked to the achievement of preclinical, clinical, regulatory and commercial objectives. as well as royalties on potential net sales.
This versatile technology makes it possible to create a whole new class of molecules that induce synthetic immunity against cancer. In addition to exploiting their anti-tumor functions, this technology makes it possible to give a targeted proliferation and activation signal to NK cells.